Tag: metabolic disease
-
Amylyx Turns GLP-1 Biology in the Opposite Direction
Avexitide met the primary endpoint in the Phase 3 LUCIDITY trial, reducing Level 2 and Level 3 hypoglycemic events by 55% versus placebo in patients with post-bariatric hypoglycemia.
-
Eli Lilly Advances Obesity Drug Pipeline After Positive Phase 2 Results
Eli Lilly has advanced its novel non-incretin obesity drug into Phase 3 clinical trials after promising Phase 2 results. This move marks a significant milestone in the evolving obesity-treatment landscape, as the company explores mechanisms beyond the incretin pathway. The announcement highlights the growing diversification of obesity therapies and intensifying competition among global pharma leaders.